Standardized SEC financial data for MERIDIAN BIOSCIENCE INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000794172 · In Vitro & In Vivo Diagnostic Substances.
| USD | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Revenue | $200.8M | $213.6M | $201.0M | $253.7M | $317.9M | $333.0M |
| Cost of revenue | $76.5M | $82.5M | $82.3M | $97.4M | $116.7M | $144.7M |
| Gross profit | $124.3M | $131.0M | $118.7M | $156.2M | $201.1M | $188.4M |
| R&D expense | $16.0M | $16.6M | $17.8M | $23.7M | $23.9M | $24.3M |
| SG&A expense | $32.4M | $35.8M | $34.0M | $44.3M | $49.5M | $57.1M |
| Operating income | $37.4M | $31.6M | $32.7M | $61.3M | $93.0M | $54.4M |
| EBITDA | $46.5M | $40.3M | $42.7M | $74.9M | $108.3M | $70.9M |
| Interest expense | $1.6M | $1.5M | $1.9M | $2.7M | $1.9M | $1.2M |
| Pretax income | $36.4M | $30.4M | $31.6M | $59.3M | $90.5M | $54.3M |
| Income tax | $14.9M | $6.5M | $7.2M | $13.1M | $19.0M | $11.9M |
| Net income | $21.6M | $23.8M | $24.4M | $46.2M | $71.4M | $42.5M |
| EPS (diluted) | $0.51 | $0.56 | $0.57 | $1.07 | $1.62 | $0.96 |
Standardized from MERIDIAN BIOSCIENCE INC's SEC filings — per-share figures split-adjusted. Full history via the API.
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/0000794172/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/0000794172/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"